MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2019 Dec 22

PMID 31861937

Citations 36

Authors

Hyun Ah Seo

Sokviseth Moeng

Seokmin Sim

Hyo Jeong Kuh

Soo Young Choi

Jong Kook Park

Affiliations

Soon will be listed here.

Abstract

The susceptibility of cancer cells to different types of treatments can be restricted by intrinsic and acquired therapeutic resistance, leading to the failure of cancer regression and remission. To overcome this problem, a combination therapy has been proposed as a fundamental strategy to improve therapeutic responses; however, resistance is still unavoidable. MicroRNA (miRNAs) are associated with cancer therapeutic resistance. The modulation of dysregulated miRNA levels through miRNA-based therapy comprising a replacement or inhibition approach has been proposed to sensitize cancer cells to other anti-cancer therapies. The combination of miRNA-based therapy with other anti-cancer therapies (miRNA-based combinatorial cancer therapy) is attractive, due to the ability of miRNAs to target multiple genes associated with the signaling pathways controlling therapeutic resistance. In this article, we present an overview of recent findings on the role of therapeutic resistance-related miRNAs in different types of cancer. We review the feasibility of utilizing dysregulated miRNAs in cancer cells and extracellular vesicles as potential candidates for miRNA-based combinatorial cancer therapy. We also discuss innate properties of miRNAs that need to be considered for more effective combinatorial cancer therapy.

Citing Articles

RGD hydrogel-loaded ADSC extracellular vesicles mitigate uranium-induced renal injury via TLR4/NF-κB pathway inhibition.

Chen X, Dai C, Zhang B, Zhang W, Huang Z, Jiang J J Nanobiotechnology. 2025; 23(1):114.

PMID: 39962465 PMC: 11834392. DOI: 10.1186/s12951-025-03176-6.

Drug repositioning based on mutual information for the treatment of Alzheimer's disease patients.

Cava C, Castiglioni I Med Biol Eng Comput. 2025; .

PMID: 39961913 DOI: 10.1007/s11517-025-03325-x.

MicroRNAs' Significance in Retinoblastoma Diagnosis and Treatment: The Little Heroes.

Zamani Sani M, Mirzaei M, Mota A, Mohammadian J, Beilankouhi E, Rahmati M Biochem Genet. 2025; .

PMID: 39862293 DOI: 10.1007/s10528-024-10976-2.

Deregulation mechanisms and therapeutic opportunities of p53-responsive microRNAs in diffuse large B-cell lymphoma.

Voropaeva E, Orlov Y, Loginova A, Seregina O, Maksimov V, Pospelova T PeerJ. 2025; 13():e18661.

PMID: 39802185 PMC: 11720970. DOI: 10.7717/peerj.18661.

Progress in Precision Medicine for Head and Neck Cancer.

Vakili S, Behrooz A, Whichelo R, Fernandes A, Emwas A, Jaremko M Cancers (Basel). 2024; 16(21).

PMID: 39518152 PMC: 11544984. DOI: 10.3390/cancers16213716.

References

Chanmee T, Ontong P, Mochizuki N, Kongtawelert P, Konno K, Itano N . Excessive hyaluronan production promotes acquisition of cancer stem cell signatures through the coordinated regulation of Twist and the transforming growth factor β (TGF-β)-Snail signaling axis. J Biol Chem. 2014; 289(38):26038-26056. PMC: 4176217. DOI: 10.1074/jbc.M114.564120. View

Park M, Hong J . Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches. Cells. 2016; 5(2). PMC: 4931664. DOI: 10.3390/cells5020015. View

Moskwa P, Buffa F, Pan Y, Panchakshari R, Gottipati P, Muschel R . miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011; 41(2):210-20. PMC: 3249932. DOI: 10.1016/j.molcel.2010.12.005. View

Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y, Ngankeu A . EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 2011; 18(1):74-82. PMC: 3467100. DOI: 10.1038/nm.2577. View

Elgamal O, Park J, Gusev Y, Azevedo-Pouly A, Jiang J, Roopra A . Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation. PLoS One. 2013; 8(10):e76402. PMC: 3788717. DOI: 10.1371/journal.pone.0076402. View

Na Y, Kim J . Understanding cooperativity of microRNAs via microRNA association networks. BMC Genomics. 2014; 14 Suppl 5:S17. PMC: 3852507. DOI: 10.1186/1471-2164-14-S5-S17. View

Xiao S, Zhang M, Liu C, Wang D . MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer. Mol Genet Genomics. 2018; 293(5):1159-1167. DOI: 10.1007/s00438-018-1447-0. View

Min Q, Wang X, Zhang J, Chen Q, Li S, Liu X . Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365. Exp Cell Res. 2017; 362(2):386-393. DOI: 10.1016/j.yexcr.2017.12.001. View

He J, Yu J, Xu Q, Wang L, Zheng J, Liu L . Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. Autophagy. 2015; 11(2):373-84. PMC: 4502709. DOI: 10.1080/15548627.2015.1009781. View

10.

Amodio N, Gallo Cantafio M, Botta C, Agosti V, Federico C, Caracciolo D . Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers (Basel). 2019; 11(2). PMC: 6406286. DOI: 10.3390/cancers11020236. View

11.

Raab-Westphal S, Marshall J, Goodman S . Integrins as Therapeutic Targets: Successes and Cancers. Cancers (Basel). 2017; 9(9). PMC: 5615325. DOI: 10.3390/cancers9090110. View

12.

Clarke P, Roe T, Swabey K, Hobbs S, McAndrew C, Tomlin K . Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer. Oncogene. 2019; 38(25):5076-5090. PMC: 6755994. DOI: 10.1038/s41388-019-0780-z. View

13.

Levine B, Kroemer G . Biological Functions of Autophagy Genes: A Disease Perspective. Cell. 2019; 176(1-2):11-42. PMC: 6347410. DOI: 10.1016/j.cell.2018.09.048. View

14.

Kozomara A, Birgaoanu M, Griffiths-Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2018; 47(D1):D155-D162. PMC: 6323917. DOI: 10.1093/nar/gky1141. View

15.

Tang B, Zhang Y, Liang R, Gao Z, Sun D, Wang L . RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug-resistant hepatocellular carcinoma cells to chemotherapy. Oncol Rep. 2013; 29(3):1037-42. DOI: 10.3892/or.2013.2222. View

16.

Meng Y, Gao R, Ma J, Zhao J, Xu E, Wang C . MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy. Sci Rep. 2017; 7(1):416. PMC: 5428500. DOI: 10.1038/s41598-017-00405-3. View

17.

Jin Y, Jiang Z, Guan X, Chen Y, Tang Q, Wang G . miR-450b-5p Suppresses Stemness and the Development of Chemoresistance by Targeting SOX2 in Colorectal Cancer. DNA Cell Biol. 2016; 35(5):249-56. DOI: 10.1089/dna.2015.3120. View

18.

Pietrocola F, Pol J, Vacchelli E, Rao S, Enot D, Baracco E . Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell. 2016; 30(1):147-160. PMC: 5715805. DOI: 10.1016/j.ccell.2016.05.016. View

19.

Santini R, Vinci M, Pandolfi S, Penachioni J, Montagnani V, Olivito B . Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells. 2012; 30(9):1808-18. DOI: 10.1002/stem.1160. View

20.

Liu X, Lu Y, Xu Y, Hou S, Huang J, Wang B . Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. Cancer Lett. 2019; 459:122-134. DOI: 10.1016/j.canlet.2019.05.035. View